Live Attenuated freeze-dried Influenza Vaccine has been licensed for use in 2020 (Approval No.S20200002), the sponsor of this research submitted an new application for non freeze-dried Live Attenuated Influenza Vaccine in 2021. The main objective of phase trail is to evaluate the safety of LAVI(non freeze-dried). The secondary objective is to evaluate the immunogenicity of LAVI(non freeze-dried).
Totally 160 health people aged 3-59 years old will be divided into two age group, containing 80 in 18-59 years old and 80 in 3-19 years old. All subjects will receive vaccination either LAVI or placebo in a ratio of 3:1.
All subjects will be collected any adverse events within 30 days and any serious adverse events within 6 months for safety evaluation.
All subjects will be collected blood sample and nasopharyngeal swab for immunogenicity evaluation.
| Condition | Influenza Prevention |
|---|---|
| Treatment | Live Attenuated Influenza Vaccine, Live Attenuated Influenza Vaccine, Live Attenuated Influenza Vaccine placebo |
| Clinical Study Identifier | NCT05056519 |
| Sponsor | Changchun BCHT Biotechnology Co. |
| Last Modified on | 28 May 2022 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.